180146-66-1

Usage

Uses

Used in Pharmaceutical Industry:
[3-NITRO-5-(TRIFLUOROMETHYL)PHENYL]METHANOL is used as a building block for the production of pharmaceuticals. The presence of the nitro group makes [3-NITRO-5-(TRIFLUOROMETHYL)PHENYL]METHANOL useful in the preparation of various fluorinated organic compounds with potential biological and pharmaceutical applications.
Used in Agrochemical Industry:
[3-NITRO-5-(TRIFLUOROMETHYL)PHENYL]METHANOL is used as a key component in the synthesis of agrochemicals. Its ability to introduce the trifluoromethyl group into compounds makes it a valuable asset in the development of new and effective agrochemical products.
Used in Organic Synthesis:
[3-NITRO-5-(TRIFLUOROMETHYL)PHENYL]METHANOL is used as a reagent in organic synthesis to introduce the trifluoromethyl group into various compounds, which can enhance their properties and make them more suitable for specific applications.
Used in Drug Discovery and Development:
[3-NITRO-5-(TRIFLUOROMETHYL)PHENYL]METHANOL is used as a valuable compound in drug discovery and development processes. The trifluoromethyl group can improve the lipophilicity and metabolic stability of drugs, making [3-NITRO-5-(TRIFLUOROMETHYL)PHENYL]METHANOL an important tool in the creation of more effective medications.

InChI:InChI=1/C8H6F3NO3/c9-8(10,11)6-1-5(4-13)2-7(3-6)12(14)15/h1-3,13H,4H2

Upstream product

• 328-80-3 3-nitro-5-trifluoromethyl-benzoic acid 
• 22227-63-0 methyl 3-nitro-5-(trifluoromethyl)-benzoate 
• 454-92-2 3-(trifluoromethyl)benzoic acid 

Downstream Products

• 632353-50-5 3-nitro-5-(trifluoromethyl)benzyl methanesulfonate 
• 180146-67-2 1-(bromomethyl)-3-nitro-5-(trifluoromethyl)benzene 
• 284047-98-9 3-nitro-5-(trifluoromethyl)benzaldehyde 
• 537039-44-4 [3-amino-5-(trifluoromethyl)phenyl]methanol 
• 880882-03-1 1-(methoxymethyl)-3-nitro-5-(trifluoromethyl)benzene 
• 1044271-89-7 1-(chloromethyl)-3-nitro-5-(trifluoromethyl)benzene 
• 853296-94-3 3-[(4-methylpiperazin-1-yl)methyl]-5-(trifluoro-methyl)aniline 
• 942076-92-8 1-methyl-4-[[3-nitro-5-(trifluoromethyl)phenyl]methyl]piperazine 
• 1274816-89-5 tert-butyl [3-amino-5-(trifluoromethyl)benzyl]isopropylcarbamate 
• 1274816-97-5 tert-butyl isopropyl[3-nitro-5-(trifluoromethyl)benzyl]carbamate 
• 1274816-96-4 N-[3-nitro-5-(trifluoromethyl)benzyl]propan-2-amine 
• 697305-66-1 N,N-dimethyl-1-[3-nitro-5-(trifluoromethyl)phenyl]methanamine 

Relevant academic research and scientific papers

2-((3,5-Dinitrobenzyl)thio)quinazolinones: Potent Antimycobacterial Agents Activated by Deazaflavin (F420)-Dependent Nitroreductase (Ddn)

Swapping the substituents in positions 2 and 4 of the previously synthesized but yet undisclosed 5-cyano-4-(methylthio)-2-arylpyrimidin-6-ones 4, ring closure, and further optimization led to the identification of the potent antitubercular 2-thio-substituted quinazolinone 26. Structure-activity relationship (SAR) studies indicated a crucial role for both meta-nitro substituents for antitubercular activity, while the introduction of polar substituents on the quinazolinone core allowed reduction of bovine serum albumin (BSA) binding (63c, 63d). While most of the tested quinazolinones exhibited no cytotoxicity against MRC-5, the most potent compound 26 was found to be mutagenic via the Ames test. This analogue exhibited moderate inhibitory potency against Mycobacterium tuberculosis thymidylate kinase, the target of the 3-cyanopyridones that lies at the basis of the current analogues, indicating that the whole-cell antimycobacterial activity of the present S-substituted thioquinazolinones is likely due to modulation of alternative or additional targets. Diminished antimycobacterial activity was observed against mutants affected in cofactor F420 biosynthesis (fbiC), cofactor reduction (fgd), or deazaflavin-dependent nitroreductase activity (rv3547), indicating that reductive activation of the 3,5-dinitrobenzyl analogues is key to antimycobacterial activity.

Development of 3,5-Dinitrophenyl-Containing 1,2,4-Triazoles and Their Trifluoromethyl Analogues as Highly Efficient Antitubercular Agents Inhibiting Decaprenylphosphoryl-β- d -ribofuranose 2′-Oxidase

We report herein the discovery of 3,5-dinitrophenyl 1,2,4-triazoles with excellent and selective antimycobacterial activities against Mycobacterium tuberculosis strains, including clinically isolated multidrug-resistant strains. Thorough structure-activity relationship studies of 3,5-dinitrophenyl-containing 1,2,4-triazoles and their trifluoromethyl analogues revealed the key role of the position of the 3,5-dinitrophenyl fragment in the antitubercular efficiency. Among the prepared compounds, the highest in vitro antimycobacterial activities against M. tuberculosis H37Rv and against seven clinically isolated multidrug-resistant strains of M. tuberculosis were found with S-substituted 4-alkyl-5-(3,5-dinitrophenyl)-4H-1,2,4-triazole-3-thiols and their 3-nitro-5-(trifluoromethyl)phenyl analogues. The minimum inhibitory concentrations of these compounds reached 0.03 μM, which is superior to all the current first-line anti-tuberculosis drugs. Furthermore, almost all compounds with excellent antimycobacterial activities exhibited very low in vitro cytotoxicities against two proliferating mammalian cell lines. The docking study indicated that these compounds acted as the inhibitors of decaprenylphosphoryl-β-d-ribofuranose 2′-oxidase enzyme, which was experimentally confirmed by two independent radiolabeling experiments.

Development of 3,5-Dinitrobenzylsulfanyl-1,3,4-oxadiazoles and Thiadiazoles as Selective Antitubercular Agents Active Against Replicating and Nonreplicating Mycobacterium tuberculosis

Herein, we report the discovery and structure-activity relationships of 5-substituted-2-[(3,5-dinitrobenzyl)sulfanyl]-1,3,4-oxadiazoles and 1,3,4-thiadiazoles as a new class of antituberculosis agents. The majority of these compounds exhibited outstanding in vitro activity against Mycobacterium tuberculosis CNCTC My 331/88 and six multidrug-resistant clinically isolated strains of M. tuberculosis, with minimum inhibitory concentration values as low as 0.03 μM (0.011-0.026 μg/mL). The investigated compounds had a highly selective antimycobacterial effect because they showed no activity against the other bacteria or fungi tested in this study. Furthermore, the investigated compounds exhibited low in vitro toxicities in four proliferating mammalian cell lines and in isolated primary human hepatocytes. Several in vitro genotoxicity assays indicated that the selected compounds have no mutagenic activity. The oxadiazole and thiadiazole derivatives with the most favorable activity/toxicity profiles also showed potency comparable to that of rifampicin against the nonreplicating streptomycin-starved M. tuberculosis 18b-Lux strain, and therefore, these derivatives, are of particular interest.

PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS

JAK1 inhibitors of structural formula (I), wherein Ar1, Ar2, Q, W, X, Y, and Z are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

Design and optimization of potent and orally bioavailable tetrahydronaphthalene raf inhibitors

Inhibition of mutant B-Raf signaling, through either direct inhibition of the enzyme or inhibition of MEK, the direct substrate of Raf, has been demonstrated preclinically to inhibit tumor growth. Very recently, treatment of B-Raf mutant melanoma patients with a selective B-Raf inhibitor has resulted in promising preliminary evidence of antitumor activity. This article describes the design and optimization of tetrahydronaphthalene-derived compounds as potent inhibitors of the Raf pathway in vitro and in vivo. These compounds possess good pharmacokinetic properties in rodents and inhibit B-Raf mutant tumor growth in mouse xenograft models.

QUINAZOLINONE DERIVATIVES HAVING B-RAF INHIBITORY ACTIVITY

The invention relates to chemical compounds of the formula (I) or pharmaceutically acceptable salts thereof, which possess B Raf inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm blooded animal such as man.

Pteridinone derivatives as PI3-kinases inhibitors

New compounds of formula 1 are provided which by virtue of their pharmaceutical activity as PI3-kinase modulators may be used in the therapeutic field for the treatment of inflammatory or allergic diseases. Examples of these include inflammatory and allergic respiratory complaints, inflammatory diseases of the gastro-intestinal tract and motor apparatus, inflammatory and allergic skin diseases, inflammatory eye diseases, diseases of the nasal mucosa, inflammatory or allergic conditions involving autoimmune reactions or inflammations of the kidney.

QUINAZOLIN-4-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The invention relates to chemical compounds of the formula (I): or pharmaceutically acceptable salts thereof, which possess B-Raf inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.

NK-1 AND SEROTONIN TRANSPORTER INHIBITORS

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or serotonin or both.

TRISUBSTITUTED AMINE COMPOUND

The present invention relates to a compound of the general formula (1): wherein, Y is a methylene group, and the like; A is an optionally substituted heterocyclic group, and the like; B is an optionally substituted heterocyclic group, and the like; R1 is an optionally substituted alkyl group, wherein the alkyl group further may optionally be substituted by an optionally substituted homocyclic group, and the like; and R2 is an optionally substituted amino group, and the like; or a pharmaceutically acceptable derivative thereof, which has an inhibitory activity against cholesteryl ester transfer protein (CETP), thereby being useful for prophylaxis and/or treatment of arteriosclerotic diseases, hyperlipemia or dyslipidemia, and the like.